NCT02251548 - A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

January 31, 2025

Study Completion Date

January 31, 2027

Conditions

Chronic Lymphocytic LeukemiaLeukemia

Interventions

DRUG

Ibrutinib

Oral BTK inhibitor

DRUG

Fludarabine

IV purine analogue chemotherapy agent

DRUG

Cyclophosphamide

IV alkylator chemotherapy agent

DRUG

Rituximab

IV anti-CD20 monoclonal antibody

Trial Locations (9)

Duke University Medical Center, Durham

Unversity of Miami Sylvester Comprehensve Cancer Center, Miami

University of Miami Sylvester Comprehensive Cancer Center, Coral Gables

University of Miami Sylvester Comprehensive Cancer Center, Deerfield Beach

West Michigan Cancer Center, Kalamazoo

University of Kansas Cancer Center, Westwood

Massachusetts General Hospital, Boston

Beth Israel Deaconess Medical Center, Boston

Dana Farber Cancer Institute, Boston